Quoin Pharmaceuticals Ltd. American Depositary Shares QNRX · Stock Open Quoin Pharmaceuticals Ltd. American Depositary Shares in new tab
Quoin Pharmaceuticals Ltd. American Depositary Shares Analysis (QNRX)
Is Quoin Pharmaceuticals Ltd. American Depositary Shares a good investment? Quoin Pharmaceuticals Ltd. American Depositary Shares (QNRX) is currently trading at 4.72 USD. Market analysts have a consensus price target of 21.83 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 0.01. This relatively low multiple may signal that Quoin Pharmaceuticals Ltd. American Depositary Shares is undervalued compared to historical market norms.
Earnings Schedule: Quoin Pharmaceuticals Ltd. American Depositary Shares is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -3.19.
Investor FAQ
Does Quoin Pharmaceuticals Ltd. American Depositary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Quoin Pharmaceuticals Ltd. American Depositary Shares?
Quoin Pharmaceuticals Ltd. American Depositary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -5.96.
Company Profile
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 23, 2019 | 1:5 |
| Sept. 24, 2021 | 1:4 |
| Aug. 1, 2022 | 0.08 |
| July 18, 2023 | 0.08 |
| April 9, 2025 | 0.03 |
Community Discussion